Nurix Therapeutics Inc (NRIX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 29.03 is considered Overvalued compared with the five-year average of -5.44. The fair price of Nurix Therapeutics Inc (NRIX) is between 4.13 to 13.26 according to relative valuation method. Compared to the current price of 15.81 USD , Nurix Therapeutics Inc By Overvalued By 19.21%.

Relative Value

Fair Zone

4.13-13.26

Current Price：15.81

19.21%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Nurix Therapeutics Inc (NRIX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Nurix Therapeutics Inc (NRIX) has a current Price-to-Book (P/B) ratio of 3.73. Compared to its 3-year average P/B ratio of 2.58, the current P/B ratio is approximately 44.81% higher. Relative to its 5-year average P/B ratio of 2.68, the current P/B ratio is about 39.32% higher. Nurix Therapeutics Inc (NRIX) has a Forward Free Cash Flow (FCF) yield of approximately -13.18%. Compared to its 3-year average FCF yield of -22.95%, the current FCF yield is approximately -42.56% lower. Relative to its 5-year average FCF yield of -20.17%, the current FCF yield is about -34.65% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NRIX competitors is 10.00, providing a benchmark for relative valuation. Nurix Therapeutics Inc Corp (NRIX.O) exhibits a P/S ratio of 29.03, which is 190.4% above the industry average. Given its robust revenue growth of 2.21%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NRIX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NRIX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NRIX currently overvalued or undervalued?

What is Nurix Therapeutics Inc (NRIX) fair value?

NRIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Nurix Therapeutics Inc (NRIX) is between 4.13 to 13.26 according to relative valuation method.

How does NRIX's valuation metrics compare to the industry average?

The average P/S ratio for NRIX's competitors is 10.00, providing a benchmark for relative valuation. Nurix Therapeutics Inc Corp (NRIX) exhibits a P/S ratio of 29.03, which is 190.40% above the industry average. Given its robust revenue growth of 2.21%, this premium appears unsustainable.

What is the current P/B ratio for Nurix Therapeutics Inc (NRIX) as of Mar 03 2026?

As of Mar 03 2026, Nurix Therapeutics Inc (NRIX) has a P/B ratio of 3.73. This indicates that the market values NRIX at 3.73 times its book value.

What is the current FCF Yield for Nurix Therapeutics Inc (NRIX) as of Mar 03 2026?

As of Mar 03 2026, Nurix Therapeutics Inc (NRIX) has a FCF Yield of -13.18%. This means that for every dollar of Nurix Therapeutics Inc's market capitalization, the company generates -13.18 cents in free cash flow.

What is the current Forward P/E ratio for Nurix Therapeutics Inc (NRIX) as of Mar 03 2026?

As of Mar 03 2026, Nurix Therapeutics Inc (NRIX) has a Forward P/E ratio of -5.19. This means the market is willing to pay $-5.19 for every dollar of Nurix Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Nurix Therapeutics Inc (NRIX) as of Mar 03 2026?

As of Mar 03 2026, Nurix Therapeutics Inc (NRIX) has a Forward P/S ratio of 29.03. This means the market is valuing NRIX at $29.03 for every dollar of expected revenue over the next 12 months.

NRIX Valuation